{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:32:31Z","timestamp":1780439551264,"version":"3.54.1"},"reference-count":40,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The assessment of treatment response is a crucial step for patients with relapsing-remitting multiple sclerosis on disease-modifying therapies (DMTs). We explored whether a scoring system developed within the MAGNIMS (MRI in Multiple Sclerosis) network to evaluate treatment response to injectable drugs can be adopted also to oral DMTs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicentre dataset of 1200 patients who started three oral DMTs (fingolimod, teriflunomide and dimethyl fumarate) was collected within the MAGNIMS network. Disease activity after the first year was classified by the \u2018MAGNIMS\u2019 score based on the combination of relapses (0\u2013\u22652) and\/or new T2 lesions (&lt;3\u2009or \u22653) on brain MRI. We explored the association of this score with the following 3-year outcomes: (1) confirmed disability worsening (CDW); (2) treatment failure (TFL); (3) relapse count between years 1 and 3. The additional value of contrast-enhancing lesions (CELs) and lesion location was explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 3 years, 160 patients experienced CDW: 12% of them scored \u20180\u2019 (reference), 18% scored \u20181\u2019 (HR=1.82, 95% CI 1.20 to 2.76, p=0.005) and 37% scored \u20182\u2019 (HR=2.74, 95% CI 1.41 to 5.36, p=0.003) at 1\u2009year. The analysis of other outcomes provided similar findings. Considering the location of new T2 lesions (supratentorial vs infratentorial\/spinal cord) and the presence of CELs improved the prediction of CDW and TFL, respectively, in patients with minimal MRI activity alone (one or two new T2 lesions).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2023-331920","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T17:20:23Z","timestamp":1696008023000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study"],"prefix":"10.1136","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5287-3290","authenticated-orcid":false,"given":"Serena","family":"Ruggieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6267","authenticated-orcid":false,"given":"Luca","family":"Prosperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmad","family":"Al-Araji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Osvaldo","family":"Annovazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7202-4445","authenticated-orcid":false,"given":"Alvino","family":"Bisecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3293-5121","authenticated-orcid":false,"given":"Vinzenz","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Evangelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9271-346X","authenticated-orcid":false,"given":"Afagh","family":"Garjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Groppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom","family":"Haggiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-3328","authenticated-orcid":false,"given":"Michael","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0447-2297","authenticated-orcid":false,"given":"Matteo","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-0019","authenticated-orcid":false,"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4320","authenticated-orcid":false,"given":"Maria A","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2132-6750","authenticated-orcid":false,"given":"Alex","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L","family":"Stromillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9037-7300","authenticated-orcid":false,"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-4067","authenticated-orcid":false,"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"2024011107550754000_95.2.142.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0170-8"},{"key":"2024011107550754000_95.2.142.2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0000000000006810","article-title":"Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge","volume":"92","author":"Gasperini","year":"2019","journal-title":"Neurology"},{"key":"2024011107550754000_95.2.142.3","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509104591"},{"key":"2024011107550754000_95.2.142.4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23758"},{"key":"2024011107550754000_95.2.142.5","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514527863"},{"key":"2024011107550754000_95.2.142.6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/WNL.0000000000002830","article-title":"Assessing response to interferon-\u0392 in a multicenter Dataset of patients with MS","volume":"87","author":"Sormani","year":"2016","journal-title":"Neurology"},{"key":"2024011107550754000_95.2.142.7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1352458517698052","article-title":"Disability progression markers over 6-12\u2009years in interferon-\u0392-treated multiple sclerosis patients","volume":"24","author":"R\u00edo","year":"2018","journal-title":"Mult Scler"},{"key":"2024011107550754000_95.2.142.8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322348"},{"key":"2024011107550754000_95.2.142.9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jns.2015.09.010","article-title":"Prediction of disability progression in Fingolimod-treated patients","volume":"358","author":"Lattanzi","year":"2015","journal-title":"J Neurol Sci"},{"key":"2024011107550754000_95.2.142.10","doi-asserted-by":"crossref","unstructured":"Sormani MP , Truffinet P , Thangavelu K , et al . Predicting long-term disability outcomes in patients with MS treated with Teriflunomide in TEMSO. Neurol Neuroimmunol Neuroinflamm 2017;4:e379. doi:10.1212\/NXI.0000000000000379","DOI":"10.1212\/NXI.0000000000000379"},{"key":"2024011107550754000_95.2.142.11","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1177\/1352458520961690","article-title":"Early evidence of disease activity during Fingolimod predicts medium-term Inefficacy in relapsing-remitting multiple sclerosis","volume":"27","author":"Ferr\u00e8","year":"2021","journal-title":"Mult Scler"},{"key":"2024011107550754000_95.2.142.12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2016.12.012","article-title":"Lymphocyte Subsets as biomarkers of therapeutic response in Fingolimod treated relapsing multiple sclerosis patients","volume":"303","author":"Paolicelli","year":"2017","journal-title":"J Neuroimmunol"},{"key":"2024011107550754000_95.2.142.13","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/cns.12851","article-title":"Predicting therapeutic response to Fingolimod treatment in multiple sclerosis patients","volume":"24","author":"Quirant-S\u00e1nchez","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"2024011107550754000_95.2.142.14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and dimethyl-fumarate-derived Lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"key":"2024011107550754000_95.2.142.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"2024011107550754000_95.2.142.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2024011107550754000_95.2.142.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2024011107550754000_95.2.142.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"2024011107550754000_95.2.142.19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/2013.jamaneurol.211","article-title":"Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic","volume":"70","author":"Erbayat Altay","year":"2013","journal-title":"JAMA Neurol"},{"key":"2024011107550754000_95.2.142.20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.msard.2016.05.012","article-title":"A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with interferon beta","volume":"8","author":"Galassi","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"2024011107550754000_95.2.142.21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2015.12.043","article-title":"Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis","volume":"361","author":"R\u00edo","year":"2016","journal-title":"J Neurol Sci"},{"key":"2024011107550754000_95.2.142.22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024011107550754000_95.2.142.23","doi-asserted-by":"crossref","unstructured":"Prosperini L , Ruggieri S , Haggiag S , et al . Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2021;8:e1059. doi:10.1212\/NXI.0000000000001059","DOI":"10.1212\/NXI.0000000000001059"},{"key":"2024011107550754000_95.2.142.24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac111"},{"key":"2024011107550754000_95.2.142.25","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1111\/ene.14845","article-title":"Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the road score","volume":"28","author":"Gasperini","year":"2021","journal-title":"Eur J Neurol"},{"key":"2024011107550754000_95.2.142.26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00415-021-10823-z","article-title":"Treatment response scoring systems to assess long-term prognosis in self-Injectable Dmts relapsing-remitting multiple sclerosis patients","volume":"269","author":"R\u00edo","year":"2022","journal-title":"J Neurol"},{"key":"2024011107550754000_95.2.142.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.146"},{"key":"2024011107550754000_95.2.142.28","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0022-510X(11)70007-7","article-title":"Review of methodological issues of clinical trials in multiple sclerosis","volume":"311 Suppl 1","author":"Montalban","year":"2011","journal-title":"J Neurol Sci"},{"key":"2024011107550754000_95.2.142.29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1177\/1352458516687402","article-title":"Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS","volume":"23","author":"Capra","year":"2017","journal-title":"Mult Scler"},{"key":"2024011107550754000_95.2.142.30","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0140-6736(98)03053-0","article-title":"Predictive value of Gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis","volume":"353","author":"Kappos","year":"1999","journal-title":"The Lancet"},{"key":"2024011107550754000_95.2.142.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0979-5"},{"key":"2024011107550754000_95.2.142.32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181feb26f"},{"key":"2024011107550754000_95.2.142.33","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz156"},{"key":"2024011107550754000_95.2.142.34","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy352"},{"key":"2024011107550754000_95.2.142.35","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329854"},{"key":"2024011107550754000_95.2.142.36","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s00415-019-09526-3","article-title":"Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey","volume":"266","author":"Granella","year":"2019","journal-title":"J Neurol"},{"key":"2024011107550754000_95.2.142.37","doi-asserted-by":"crossref","unstructured":"Ostini C , Bovis F , Disanto G , et al . Recurrence and Prognostic value of asymptomatic spinal cord lesions in multiple sclerosis. J Clin Med 2021;10:463. doi:10.3390\/jcm10030463","DOI":"10.3390\/jcm10030463"},{"key":"2024011107550754000_95.2.142.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00504-0"},{"key":"2024011107550754000_95.2.142.39","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00415-021-10901-2","article-title":"The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI","volume":"269","author":"Di Sabatino","year":"2022","journal-title":"J Neurol"},{"key":"2024011107550754000_95.2.142.40","first-page":"1273","article-title":"Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression","volume":"27","author":"Mardan","year":"2021","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-331920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T15:58:27Z","timestamp":1704988707000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-331920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/jnnp-2023-331920"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-331920","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}